16/05/2018 18:32:21

Aquinox to Present at 2018 UBS Global Healthcare Conference

Related content
27 Jun - 
Aquinox Announces Topline Results of Phase 3 LEADERSHIP..
11 Jun - 
Aquinox Pharmaceuticals Announces Initiation of ProShip..
10 May - 
Aquinox and Astellas Announce Exclusive Licensing Agree..
Related debate
29 Jun - 
tør ikke købe idag men ingen retsager, det er usædvanli..
29 Jun - 
bemærker de har dobbelt cash af nuværende kurs, og stad..

VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 UBSGlobal Healthcare Conference in New York on Wednesday, May 23rd2018.

Aquinox Presentation Details

Date: Wednesday, May 23rd2018

Time: 5:00 am Pacific Time / 8:00 am Eastern Time                                  

Location: New York, NY – Grand Hyatt New York

A live webcast and archive of the event will be available at:

https://cc.talkpoint.com/ubsx001/052118a_as/?entity=75_XVWH8N7

To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.

About

Aquinox

Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit http://www.aqxpharma.com/.

Investor

Contact

Info:

Brendan

Payne

Associate Director, Investor Relations

Aquinox Pharmaceuticals, Inc.

604.901.3019

ir@aqxpharma.com

Gitanjali Ogawa

Vice President 

The Trout Group

646-378-2949


Gogawa@troutgroup.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
CALI INVESTOR ALERT: Rosen Law Firm Reminds China Auto Logistics Inc. Investors of Important Deadline in First Filed Class Action  - CALI
2
EQUITY NOTICE: Rosen Law Firm Announces First Filed Class Action on behalf of Glencore plc Investors – GLNCY, GLCNF
3
CLASS ACTION UPDATE for QCOM and ORA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
4
COOL NOTICE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against PolarityTE, Inc.; Important Deadline – COOL
5
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PCG, UNM, and TAL

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2018 07:19:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB3 - 2018-07-16 08:19:56 - 2018-07-16 07:19:56 - 1000 - Website: OKAY